Form 4 Apellis Pharmaceuticals, For: May 03 Filed by: Townsend Adam J.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106
May 5, 2023 11:15 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $106.00 (from $88.00) while maintaining a Buy rating.
The analyst comments "The first quarter of any drug launch is frequently a wildcard. Syfovre embodied this uncertainty given 1) mid-1Q23 approval, 2) temporary J-code,... More



